EP1213977A1 - Filtering method and filter consisting of nitrogen-containing cycles or heterocyles such as dna or rna designed in particular for filtering tobacco smoke and cigarette containing such a filter - Google Patents
Filtering method and filter consisting of nitrogen-containing cycles or heterocyles such as dna or rna designed in particular for filtering tobacco smoke and cigarette containing such a filterInfo
- Publication number
- EP1213977A1 EP1213977A1 EP00962594A EP00962594A EP1213977A1 EP 1213977 A1 EP1213977 A1 EP 1213977A1 EP 00962594 A EP00962594 A EP 00962594A EP 00962594 A EP00962594 A EP 00962594A EP 1213977 A1 EP1213977 A1 EP 1213977A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- filter
- molecules
- nitrogen
- active principle
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001914 filtration Methods 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 21
- 241000208125 Nicotiana Species 0.000 title claims abstract description 17
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 17
- 235000019504 cigarettes Nutrition 0.000 title claims description 36
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims description 12
- 239000000779 smoke Substances 0.000 title claims description 11
- 239000000835 fiber Substances 0.000 claims abstract description 34
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 19
- 229960002715 nicotine Drugs 0.000 claims abstract description 19
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 15
- 239000011737 fluorine Substances 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 235000019568 aromas Nutrition 0.000 claims abstract description 8
- 150000002367 halogens Chemical class 0.000 claims abstract description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 5
- -1 nitrogen heteroaromatics Chemical class 0.000 claims description 26
- 231100000331 toxic Toxicity 0.000 claims description 25
- 230000002588 toxic effect Effects 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims description 14
- 230000000711 cancerogenic effect Effects 0.000 claims description 13
- 231100000315 carcinogenic Toxicity 0.000 claims description 12
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical class [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 12
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 150000004005 nitrosamines Chemical class 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 5
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000003217 anti-cancerogenic effect Effects 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 230000031018 biological processes and functions Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000004172 nitrogen cycle Methods 0.000 claims description 4
- 235000011007 phosphoric acid Nutrition 0.000 claims description 4
- 239000011775 sodium fluoride Substances 0.000 claims description 4
- 235000013024 sodium fluoride Nutrition 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 3
- 102000030621 adenylate cyclase Human genes 0.000 claims description 3
- 108060000200 adenylate cyclase Proteins 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229910004877 Na2PO3F Inorganic materials 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 235000019505 tobacco product Nutrition 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 229920005594 polymer fiber Polymers 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 14
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 10
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000026030 halogenation Effects 0.000 description 4
- 238000005658 halogenation reaction Methods 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000011269 tar Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010063312 Metalloproteins Proteins 0.000 description 2
- 102000010750 Metalloproteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- YZNXOCVTNIERFC-UHFFFAOYSA-N 1-[2-(furan-2-yl)-5-hydroxy-6-(hydroxymethyl)-1,3-dioxan-4-yl]ethane-1,2-diol Chemical class O1C(CO)C(O)C(C(O)CO)OC1C1=CC=CO1 YZNXOCVTNIERFC-UHFFFAOYSA-N 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
- A24D3/06—Use of materials for tobacco smoke filters
- A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
Definitions
- the present invention relates to a filtration method and a filter for general use, especially applicable to tobacco products, and in particular for the mouthpiece of a cigarette filter.
- the object of the invention is more particularly to protect the molecules of the human genome against the toxic carcinogens of inhaled smoke.
- Cigarette filters known to date generally contain polysaccharide derivatives, of natural or thermoplastic origin, polyesters, such as polyethylene and polypropylene terephthalate.
- Patent EP 434332 and EP 434339 of RJ Reynolds Tobacco Cie describe such filters, they can also contain dried tobacco grains. In these various patents, mention is made of the use of salts, acids, bases, surfactants, in a medium with basic PH.
- patent WO 96/00019 describes a cigarette filter enriched with Fe ++, Cu ++ or Mg ++ ions.
- the objective is the retention of free radicals and particularly the protection of metalloproteins.
- WO 96/10929 describes a free radical inhibitor, such as an O-alkylated derivative of 2,4-monofurfurylidene sorbitol, associated with an antioxidant, the action of which is to filter Polycyclic Aromatic Hydrocarbons (HPA), mainly 3,4-Benzo-a-pyrene (BaP), with known carcinogenic power.
- HPA Polycyclic Aromatic Hydrocarbons
- BaP 3,4-Benzo-a-pyrene
- fluoride has anti-tumor effects. It is involved in particular in the composition of dexamethasone and 5-fluorouracil.
- the filtration process according to the invention has a selective, direct chemical, anti-carcinogenic action. It is intended to filter toxic products, in particular polycyclic aromatic hydrocarbons (HPA) such as benzo (a) pyrene (BaP) and nitrosamines, contained in the tobacco smoke of a cigarette.
- HPA polycyclic aromatic hydrocarbons
- BaP benzo
- nitrosamines contained in the tobacco smoke of a cigarette.
- the filtration process includes the step of controlling the rate of toxic products relative to that of nicotine so that the reduction in the rate at the outlet of the filter is greater than a predetermined threshold.
- One of its main properties is the selective mode of action of the process according to the invention, with respect to toxic carcinogenic products in relation to nicotine. Its second main characteristic is its direct chemical action. That is to say, its action with respect to toxic carcinogenic products at the level of the very reactive site of DNA.
- the process according to the invention comprises the following steps:
- the step of capturing all or part of the toxic products by means of an active principle acting on said toxic products according to molecular processes comparable to those according to which the DNA and / or RNA of the human cell reacts with respect said toxic products the step of controlling the operating conditions of the filter by operating in a substantially non-aqueous medium and of basic pH, preferably greater than or equal to 8,
- the step of adjusting the mass of the active principle so that it is greater than or equal to 0.1% of the mass of the cigarette filter and preferably greater than or equal to 1% of the mass of the filter.
- the inventors have noted that it is with the minimum quantities of active principle and under the operating conditions mentioned above that it is possible to control the rate of toxic products, in particular the rate of polycyclic aromatic hydrocarbons (HPA) and of nitrosamines, compared to that of nicotine.
- HPA polycyclic aromatic hydrocarbons
- nitrosamines compared to that of nicotine.
- said active principle is composed of molecules consisting of one or more nitrogen rings or nitrogen heterocycles, preferably nitrogen heteroaromatics, in particular pentacycles or hexacycles or a combination of the two.
- said active principle must be in the form:
- the molecule of the active principle is DNA and / or RNA and / or a derivative of DNA or RNA, such as for example adenosine triphosphate (ATP), adenosine monophosphate cyclic (AMP), adenyl cyclase.
- the invention also relates to a cigarette filter implementing the method described above.
- the cigarette filter according to the invention has a selective, direct chemical, anti-carcinogenic action. It is intended to filter particularly polycyclic aromatic hydrocarbons (HPA) and in particular benzo (a) pyrene (BaP) as well as nitrosamines, in retaining the nicotine level and flavor aromas for the satisfaction and pleasure of the smoker.
- the filter comprises an active principle composed of molecules consisting of one or more nitrogen cycles or nitrogen heterocycles, and in particular nitrogen heteroaromatics, in particular pentacycles or hexacycles or a combination of the two.
- said active principle must be in the form of a chain of said molecules and / or of said molecules linked to a fiber, in particular a cellulose acetate fiber, in a common chemical arrangement.
- the mass of said nitrogenous cycles or heterocycles and particularly of nitrogenous heteroaromatics is at least equal to or greater than 0.1% of the total mass of the filter.
- the medium in which said nitrogenous heterocycles or heterocycles and particularly nitrogenous heteroaromatics operate is a substantially non-aqueous medium having a basic pH. Under these operating conditions, it has been found that it is possible to substantially reduce, at the outlet of the filter, the level of polycyclic aromatic hydrocarbons relative to nicotine.
- the rate can be reduced by more than 90% by retaining the nicotine level and flavor aromas for the satisfaction and pleasure of the smoker.
- other fibers of natural or artificial origin are also used, mainly aromatics of ethylene (for example, polyethylene terephthalate), propylene (for example, polypropylene terephthalate), fluorinated salt medium.
- the molecules are made of polymer in the broad sense.
- the active principle consists exclusively of molecules and / or said polymers.
- the mass of said nitrogenous cycles or heterocycles and particularly of nitrogenous heteroaromatics is at least equal or greater than 1% of the total mass of the filter.
- the humidity level of the filter is between 5 and 10%.
- the pH of the filter is greater than 8.
- the molecule of the active principle is DNA and / or RNA and / or a derivative of DNA or RNA, such as for example adenosine triphosphate (ATP), adenosine monophosphate cyclic or adenyl cyclase.
- ATP adenosine triphosphate
- adenosine monophosphate cyclic or adenyl cyclase adenosine monophosphate cyclic or adenyl cyclase.
- toxic carcinogenic products contained in tobacco smoke, directly affecting the DNA and / or RNA molecules of the human cell, are selectively captured by the filter according to molecular processes comparable to those according to which said toxic products act on the DNA and / or RNA of the human cell.
- the molecule of the active principle is added, on at least one of the nitrogen rings or nitrogen heterocycles and particularly of the nitrogen heteroaromatics, to at least one function chosen from a group comprising the functions:
- At least one molecule of the active principle is added with one or more sugars such as ribose or deoxyribose.
- at least one molecule of the active principle is added with one or more acid functions, in particular phosphoric acid (H3PO4) pentavalent and / or another molecule comprising a trivalent phosphorus.
- H3PO4 phosphoric acid
- the polymerization is carried out in the broad sense at the level of the nitrogen cycles, that is to say nitrogen heterocycles and particularly nitrogen heteroaromatics and / or added functions and / or acids and / or sugars.
- the molecule of the active principle comprises one or more atoms and / or one or more molecules and / or one or more radicals and / or one or more ions of a halogen, such as in particular fluorine.
- the molecule of the active principle is located in a medium containing halogenated salts, in particular sodium fluoride salts
- said fiber is partially halogenated, such as in particular by fluorine.
- said fiber, partially halogenated or not is in a medium comprising atoms, molecules, radicals or ions of a halogen, such as in particular fluorine.
- the invention also relates to a method of manufacturing a filter comprising an active principle composed of chains of molecules having the characteristics defined above. Said method comprises the step of extruding and / or rolling together said chains of molecules. In the case where said molecules are linked in a chemical arrangement common to fibers, in particular cellulose acetate fibers, said manufacturing process comprises the step of extruding and / or rolling together said fibers.
- the invention also relates to a filtration device of general application comprising an active principle composed of molecules and / or fibers having the characteristics and operating under the conditions defined above.
- the filtration device according to the invention is such that said molecules and / or said fibers are incorporated into separate compartments, or in the form of grains and / or filaments.
- the filtration device according to the invention is such that said molecules and / or said fibers are present in a gelatinous, liquid or gaseous physical state.
- the filtration device can be applied to the selective filtration of toxic products.
- the filtration device according to the invention can be applied to the selective purification of tobacco smoke, in order to maintain the usual levels of nicotine, for the satisfaction of the smoker, and of tar containing the flavors of tobacco, for the preservation of the taste. .
- the invention also relates to a cigarette comprising a filtration device such as that described above.
- the cigarette according to the invention comprises a tobacco rod 2. At one end of the rod 2 is mounted a filtration device 1 such as that described above.
- the invention protects molecules in the human genome against the toxic carcinogens of tobacco smoke.
- this filter has the particularity of preserving in their entirety the usual levels of nicotine and the tars of the aromas.
- This low-cost filter the maximum efficiency of which allows practical and industrial production for the best satisfaction of the smoker and his pleasure thanks to the preservation of the taste, while considerably reducing the risks involved, particularly in the field of bronchopulmonary and cardiovascular pathology.
- the invention in question here is intended to protect the human genome from attack by carcinogens, the main process involved in the mechanism of initiation and promotion of the cancer phenomenon.
- the invention is less concerned with indirect attack processes cells produced at the level of molecules such as metalloproteins or globulins involved in the immune response system.
- the carcinogenic etiogeny is due to molecules which are not always originally found in the tobacco itself, but which are intermediate pyrolysis derivatives formed along the stem of the cigarette through a cooling corridor to the filter during inhalation-aspiration.
- These derivatives, free radicals or carbocations, are electrophilic. Free radicals and carbocations are now better known as genotoxicity agents modifying the rules of duplication of DNA and / or constituting adducts with it. They can also be responsible for disorders in the DNA coding of proteins essential for cell life.
- the invention implements molecules of which several nucleophilic nuclei prevent the electrophilic attack of these agents.
- the molecules according to the invention filter, thanks to their quantity present in the filter, the toxins whose destiny would be to have a carcinogenic action in the body of the smoker either in situ, or after a process of metabolization in the faith of the smoker.
- the compounds and radicals to be filtered constitute powerful adducts with DNA by penetration into cell nuclei or after passage, for precancerogens, by bioactivating systems of the body, and cause mutagenic and carcinogenic processes. It is known that the carcinogenic process most often involves electrophilic atoms in molecules whose transmembrane passage to the cell nucleus is favored by a medium of positive electrical density.
- nucleophilic dipoles of voltage, ⁇ electronic clouds which form nucleophilic poles of attraction for electrophilic compounds and radicals.
- the components of the filter molecules according to the invention and in particular the nucleotides of DNA and RNA, obstruct the compounds and radicals to be filtered even before they reach the human genetic heritage.
- FIG. 1 represents the diagram of an example of a molecule according to the invention.
- the radicals RI, R2, R3 and R4 are amino functions, ketones, aldehydes, methyls, alkenes, alkyls, aryls, etc. These functions, added to the molecule, can be used to filter alkyl or aryl epoxides , sulphate esters, nitrosamines with direct carcinogenic power.
- radicals RI, R2, R3 and R4 can also be one or more atoms or a radical of a halogen such as fluorine.
- the molecules of the purine or pyrimidine type can be produced in the form of filaments, single-stranded strands obtained by denaturation of DNA, or strands of RNA most often simple. It is known that DNA or RNA can be obtained by culturing microorganisms, by bursting nuclei and by a gel electrophoresis method.
- the filter can use one or more halogens, but preferably fluorine, in the form of an atom, a molecule, a radical or an ion.
- fluorine can be previously added to a phenyl nucleus possible precursor of synthesis of the molecule according to the invention via a mineral acid, a Bronsted acid, or a Lewis acid .
- halogenation the syndrome of "polymer fever" or "Influenza Like” will be avoided by carrying out a partial halogenation of the fibers.
- the halogen salts used are preferably soluble salts of alkali and alkaline earth metals, for example sodium fluoride.
- the molecules according to the invention and / or the other fibers of the filter can be extruded or rolled together with halogen salts, as for example in the manufacturing process described in patent WO / 24078 of
- Certain toxic substances are to be excluded, such as the carboxylic acids of fluorine or their precursors, particularly fluoroacetic acid as well as certain dangerous organophosphates.
- the level of halogen used will not exceed the threshold imposed by the measures to restrict biodegradation and the level of consumable fluorine.
- the filter may also have, for the fibers of the molecules according to the invention and / or for the other fibers of the filter, a distribution with a high fluorine content and then with a lower fluorine content, from the center to the periphery of the filter or vice versa, or in separate compartments arranged according to the length of the filter.
- the filter as described here, has the function of filtering more effectively electrophilic compounds and radicals such as Polycyclic Aromatic Hydrocarbons (HPA) - and especially BaP - and Nitrosamines.
- HPA Polycyclic Aromatic Hydrocarbons
- the filter also comprises, in certain variant embodiments, surfactant solvents or other materials (acids of mineral or carboxylic type, bases or salts in particular for the conservation of a certain basic PH.
- surfactant solvents or other materials ascids of mineral or carboxylic type, bases or salts in particular for the conservation of a certain basic PH.
- the molecules of the filter according to the invention operate in a basic pH of greater than or equal to 8, thereby facilitating conservation of nicotine as described above.
- the acid, base and salt functions can either be added to the molecules according to the invention and / or to the other fibers of the filter substrate, or located at their contact. They can also be used for the halogenation of the molecule of the active principle and / or of the other fibers of the filter substrate.
- the greater cleanliness of the inhaled flow, combined with an action of decluttering of the tissues, allows a very favorable prognosis as regards the limitation of bronchopulmonary, cardiovascular pathology and mutagenic or carcinogenic processes.
- the filter is used for general filtration of pollutants and toxic products.
- the filter thus described is not necessarily in contact with tobacco; it can for example be housed in a cigarette holder.
- the mass of nitrogen rings and nitrogen heterocycles and particularly of nitrogen heteroaromatics present in the filter represents at least 0.1% and, preferably, more than 1% of the total mass of the filter. Tests performed.
- Standard-size cigarette filter injected with single-stranded salmon DNA filaments composed of about a thousand nucleotides, the mass of DNA being 10 mg per cigarette filter, the filter being dried before smoking and dosage.
- Humidity level 7 ⁇ 2%, PH: about 8
- the filter is injected with single-stranded strands of salmon DNA, length of approximately 2000 base pairs and for an amount equal to 10 mg for a conventional cigarette filter.
- Humidity level 7 ⁇ 2% PH: about 8
- the filter consists on its axis of a mixed compartment of filaments of salmon DNA and polypropylene terephthalate fibers, and of a compartment consisting only of these latter fibers.
- the mass of DNA filaments representing 10 mg for a conventional cigarette filter.
- the cigarette filter is made up of a mixture of linear filaments of salmon DNA tangled with polypropylene terephthalate fibers.
- the mass of DNA filaments representing 10 mg for a conventional cigarette filter.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Cigarettes, Filters, And Manufacturing Of Filters (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9911552A FR2798302B1 (en) | 1999-09-13 | 1999-09-13 | FILTER COMPOSED OF NITROGEN HETEROCYCLES SUCH AS DNA, IN PARTICULAR FOR THE FILTRATION OF TOBACCO SMOKE, CIGARETTE COMPRISING SUCH A FILTER |
FR9911552 | 1999-09-13 | ||
PCT/FR2000/002493 WO2001019210A1 (en) | 1999-09-13 | 2000-09-08 | Filtering method and filter consisting of nitrogen-containing cycles or heterocyles such as dna or rna designed in particular for filtering tobacco smoke and cigarette containing such a filter |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1213977A1 true EP1213977A1 (en) | 2002-06-19 |
EP1213977B1 EP1213977B1 (en) | 2003-11-26 |
Family
ID=9549884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00962594A Expired - Lifetime EP1213977B1 (en) | 1999-09-13 | 2000-09-08 | Filtering method and filter consisting of nitrogen-containing cycles or heterocyles such as dna or rna designed in particular for filtering tobacco smoke and cigarette containing such a filter |
Country Status (8)
Country | Link |
---|---|
US (1) | US6866045B1 (en) |
EP (1) | EP1213977B1 (en) |
JP (1) | JP4808881B2 (en) |
AT (1) | ATE254858T1 (en) |
AU (1) | AU7426300A (en) |
DE (1) | DE60006832D1 (en) |
FR (1) | FR2798302B1 (en) |
WO (1) | WO2001019210A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1614457A1 (en) * | 2003-04-16 | 2006-01-11 | Nissei Bio Co., Ltd. | Method for removing harmful substances and filter for removing harmful substances |
US20050016555A1 (en) * | 2003-07-24 | 2005-01-27 | Lyles Mark B. | Nucleic acid based filters |
CN101166432A (en) * | 2005-04-28 | 2008-04-23 | 日生生物股份有限公司 | Cigarette filter tip capable of removing bad materials |
US20090183745A1 (en) * | 2005-10-12 | 2009-07-23 | Nissei Bio Company, Limited | Cigarette Filter |
JPWO2007083370A1 (en) * | 2006-01-18 | 2009-06-11 | 日生バイオ株式会社 | Air conditioner filter that can remove harmful substances |
JP5317394B2 (en) * | 2006-05-30 | 2013-10-16 | 株式会社ダイセル | Tobacco filter material and tobacco filter |
WO2008036388A2 (en) * | 2006-09-22 | 2008-03-27 | New York University | Methods and products for neutralizing the harmful effects of combustion products |
JP2008030039A (en) * | 2007-08-13 | 2008-02-14 | Nissei Bio Kk | Method for removing harmful substance and filter for removing harmful substance |
JP2008068254A (en) * | 2007-08-13 | 2008-03-27 | Nissei Bio Kk | Method and filter for removing harmful substance |
US9192193B2 (en) | 2011-05-19 | 2015-11-24 | R.J. Reynolds Tobacco Company | Molecularly imprinted polymers for treating tobacco material and filtering smoke from smoking articles |
US10731018B2 (en) | 2015-08-11 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Antioxidant polydihydropyridazine and polypyridazine foams from 1,2,4,5-tetrazine |
US10619023B2 (en) | 2015-08-11 | 2020-04-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Green chemistry method of synthesizing polymer structures that can function as a built-in antioxidant |
US10851192B2 (en) | 2015-08-11 | 2020-12-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Dihydropyridazine-based antioxidants and uses thereof |
WO2017172882A1 (en) * | 2016-03-29 | 2017-10-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Pyridazine and pyridazinone based foam filtration materials for removal of nucleophiles, electrophiles, and metals |
WO2018005864A1 (en) | 2016-06-29 | 2018-01-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of formation of a robust network of foam through diels-alder reaction |
US10633517B2 (en) | 2017-03-10 | 2020-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Hydrogenated tetrazine-based antioxidants and free radical reaction inhibitors and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3982897A (en) | 1972-09-25 | 1976-09-28 | Israel Herbert Scheinberg | Filter and detector and methods of using same in the removal and detection of carbon monoxide from, and in, a gas stream |
GB1503879A (en) * | 1976-02-19 | 1978-03-15 | Scheinberg I | Preparation and method of use of compounds and compositions effective for removal conversion and detection of carbon monoxide |
WO1982002820A1 (en) * | 1981-02-18 | 1982-09-02 | Pruss Guenter | Tobacco smoke filter |
US4498485A (en) * | 1982-08-05 | 1985-02-12 | Hem-Sub, Inc. | Interferon and interferon inducers combined with tobacco products |
JPS60151397U (en) * | 1984-03-21 | 1985-10-08 | ピツプフジモト株式会社 | smoking pipe |
JPS6258981A (en) * | 1985-04-08 | 1987-03-14 | 近藤 昭子 | Structure of tobacco filter part |
US4735218A (en) * | 1984-09-09 | 1988-04-05 | Kondo Akiko | Tobacco filter |
EP0434339A3 (en) | 1989-12-18 | 1991-10-09 | R.J. Reynolds Tobacco Company | Cigarette and cigarette filter element therefor |
US5105834A (en) | 1989-12-18 | 1992-04-21 | R.J. Reynolds Tobacco Company | Cigarette and cigarette filter element therefor |
US5746231A (en) | 1993-01-11 | 1998-05-05 | Craig Lesser | Tobacco smoke filter for removing toxic compounds |
RU2123271C1 (en) | 1994-06-27 | 1998-12-20 | Ставридис Иоаннис | Method of manufacturing filter for tobacco smoke, filter, cigarette, and method of filtering tobacco smoke |
LU88544A1 (en) | 1994-10-07 | 1996-04-29 | G L A D S A | Anticarcinogenic treatment for cigarette filters or the like |
-
1999
- 1999-09-13 FR FR9911552A patent/FR2798302B1/en not_active Expired - Fee Related
-
2000
- 2000-09-08 EP EP00962594A patent/EP1213977B1/en not_active Expired - Lifetime
- 2000-09-08 WO PCT/FR2000/002493 patent/WO2001019210A1/en active IP Right Grant
- 2000-09-08 JP JP2001522862A patent/JP4808881B2/en not_active Expired - Fee Related
- 2000-09-08 US US10/088,007 patent/US6866045B1/en not_active Expired - Fee Related
- 2000-09-08 AU AU74263/00A patent/AU7426300A/en not_active Abandoned
- 2000-09-08 DE DE60006832T patent/DE60006832D1/en not_active Expired - Lifetime
- 2000-09-08 AT AT00962594T patent/ATE254858T1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO0119210A1 * |
Also Published As
Publication number | Publication date |
---|---|
ATE254858T1 (en) | 2003-12-15 |
FR2798302B1 (en) | 2001-12-21 |
FR2798302A1 (en) | 2001-03-16 |
JP2003509033A (en) | 2003-03-11 |
JP4808881B2 (en) | 2011-11-02 |
DE60006832D1 (en) | 2004-01-08 |
EP1213977B1 (en) | 2003-11-26 |
US6866045B1 (en) | 2005-03-15 |
AU7426300A (en) | 2001-04-17 |
WO2001019210A1 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1213977B1 (en) | Filtering method and filter consisting of nitrogen-containing cycles or heterocyles such as dna or rna designed in particular for filtering tobacco smoke and cigarette containing such a filter | |
US7025067B2 (en) | Activated charcoal filter for effectively reducing p-benzosemiquinone from the mainstream cigarette smoke | |
KR100265506B1 (en) | Filter cigarette | |
US20110155154A1 (en) | Smoking Article with Tobacco Beads | |
FR2542581A1 (en) | METHOD AND ENVELOPE OF A SMOKING ARTICLE FOR REDUCING THE AUXILIARY CURRENT OF SMOKE | |
US8011373B2 (en) | Method of treating tobacco extract solution to reduce magnesium ions and method of manufacturing a treated tobacco material | |
CN111655051A (en) | Biodegradable filter to improve taste | |
EP0436599A1 (en) | Tobacco smoke filters and process for production thereof | |
CN104270968A (en) | Liquid tobacco compositions | |
CA2464149A1 (en) | Cigarette filter and filter-tipped cigarette | |
EP1541044B1 (en) | Filter for cigarette | |
EP1541043B1 (en) | Filter for cigarette | |
CN1897833B (en) | Tobacco smoke filter | |
BE1020864A3 (en) | COMBINATION IN THE FORM OF POWDER HAVING PRESERVATIVE PROPERTIES, RETENTRICE OF WATER AND TEXTURANT. | |
CN202026791U (en) | Multi-element composite filter stick | |
FR2459011A1 (en) | METHOD OF AROMATING TOBACCO SMOKE, CIGARETTE TIP FOR IMPLEMENTING SAID METHOD AND APPLICATION OF THE PROCESS | |
US20050016555A1 (en) | Nucleic acid based filters | |
CA3211812A1 (en) | Liquid composition for inhalation for electronic cigarettes | |
JP2001352963A (en) | Cigarette filter and cigarette therewith | |
CH649007A5 (en) | TOBACCO SMOKE FILTER. | |
CH622687A5 (en) | Smokeable substance | |
CN101166432A (en) | Cigarette filter tip capable of removing bad materials | |
FR2767649A1 (en) | Method of production of non-tobacco cigarettes | |
JP2017513518A (en) | Additive-carrying composition | |
EP4544927A1 (en) | Filter for smoking article containing lyocell tow, manufacturing method, and smoking article comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020409 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20020903 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031126 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20031126 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031126 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031126 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031126 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031126 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 60006832 Country of ref document: DE Date of ref document: 20040108 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: FRENCH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040226 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040226 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040226 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040309 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20040317 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20031126 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040930 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040930 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040930 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040827 |
|
BERE | Be: lapsed |
Owner name: *MAILLARD FREDERIC Effective date: 20040930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
BERE | Be: lapsed |
Owner name: *MAILLARD FREDERIC Effective date: 20040930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040426 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20110127 AND 20110202 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20120925 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20121026 Year of fee payment: 13 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130908 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140530 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 |